G-BA assessment of CAR-T therapy Tecartus
The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell
Category: Early benefit assessments
G-BA assessments of new indications
The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1
Joint HTAs are finally coming to Germany
It’s been a long time in the making, but now the G-BA finally accepted a compromise on joint HTAs conducted at the
G-BA meetings
Ever wondered if patients influence the G-BA decision-making?